Amneal Pharmaceuticals

AMRX · NASDAQ

$19.84+$0.48 (+2.48%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $19.36

AMRX analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $22.76 (+14.7% upside)

Low: $19.41
Now: $19.84
High: $28.35

Upgrades and downgrades

The latest rating actions, newest first

AMRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Oppenheimer	Sep 23, 2026	Initiates	Outperform	$27.00	59%
Barclays	Sep 17, 2026	Maintains	Overweight	$16.00 → $20.00	53%
Leerink Partners	Sep 9, 2026	Initiates	Outperform	$23.00	58%
JP Morgan	Aug 26, 2026	Initiates	Overweight	$22.00	65%
UBS	Aug 3, 2026	Maintains	Buy	$23.00 → $25.00	56%
UBS	Jul 15, 2026	Maintains	Buy	$19.00 → $23.00	56%
Barclays	May 20, 2026	Maintains	Overweight	$15.00 → $16.00	53%
UBS	Apr 17, 2026	Initiates	Buy	$19.00	56%
Truist Securities	Mar 2, 2026	Maintains	Buy	$15.00 → $17.00	59%
Barclays	Dec 9, 2025	Initiates	Overweight	$15.00	53%

The case for and against

Updated Nov 29, 2024

Bull case

Amneal Pharmaceuticals has demonstrated strong commercial execution, particularly in its Generics segment, evidenced by exceeding revenue estimates by 2% in 3Q23, with a forecasted $200 million in Biosimilars sales by 2025 and additional growth projected from a new injectable portfolio. The company is well positioned for significant EBITDA growth due to its recent investments and the anticipated easing of market headwinds, with a goal to deleverage to below 4x by the end of 2025. Furthermore, the injectables segment is expected to leverage ongoing market shortages and supply chain challenges among competitors, positioning Amneal to capture additional market share in the pharmaceutical sector.

Bear case

Amneal Pharmaceuticals Inc. has faced challenges in its Specialty segment, reporting a revenue miss of 9% primarily due to disappointing Rytary sales, which declined by 6% year-over-year despite script growth. The company is at risk of delayed generic approvals and increasing competitive pressures, which could impede revenue growth and profitability across its Generics segment. Additionally, factors such as cost synergies not being realized, ongoing opioid litigation liabilities, and issues related to manufacturing quality further contribute to a negative outlook on the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.